112 related articles for article (PubMed ID: 28674152)
1. Human Arylamine
Xu X; Mathieu C; Berthelet J; Duval R; Bui LC; Busi F; Dupret JM; Rodrigues-Lima F
Mol Pharmacol; 2017 Sep; 92(3):358-365. PubMed ID: 28674152
[TBL] [Abstract][Full Text] [Related]
2. The human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) is irreversibly inhibited by inorganic (Hg2+) and organic mercury (CH3Hg+): mechanism and kinetics.
Ragunathan N; Busi F; Pluvinage B; Sanfins E; Dupret JM; Rodrigues-Lima F; Dairou J
FEBS Lett; 2010 Aug; 584(15):3366-9. PubMed ID: 20591428
[TBL] [Abstract][Full Text] [Related]
3. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition.
Ragunathan N; Dairou J; Pluvinage B; Martins M; Petit E; Janel N; Dupret JM; Rodrigues-Lima F
Mol Pharmacol; 2008 Jun; 73(6):1761-8. PubMed ID: 18310302
[TBL] [Abstract][Full Text] [Related]
4. Acrolein, an α,β-unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine N-acetyltransferase 1.
Bui LC; Manaa A; Xu X; Duval R; Busi F; Dupret JM; Rodrigues-Lima F; Dairou J
Drug Metab Dispos; 2013 Jul; 41(7):1300-5. PubMed ID: 23633528
[TBL] [Abstract][Full Text] [Related]
5. Redox regulation of the human xenobiotic metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1). Reversible inactivation by hydrogen peroxide.
Atmane N; Dairou J; Paul A; Dupret JM; Rodrigues-Lima F
J Biol Chem; 2003 Sep; 278(37):35086-92. PubMed ID: 12832400
[TBL] [Abstract][Full Text] [Related]
6. Peroxynitrite irreversibly inactivates the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) in human breast cancer cells: a cellular and mechanistic study.
Dairou J; Atmane N; Rodrigues-Lima F; Dupret JM
J Biol Chem; 2004 Feb; 279(9):7708-14. PubMed ID: 14672957
[TBL] [Abstract][Full Text] [Related]
7. Identification of cancer chemopreventive isothiocyanates as direct inhibitors of the arylamine N-acetyltransferase-dependent acetylation and bioactivation of aromatic amine carcinogens.
Duval R; Xu X; Bui LC; Mathieu C; Petit E; Cariou K; Dodd RH; Dupret JM; Rodrigues-Lima F
Oncotarget; 2016 Feb; 7(8):8688-99. PubMed ID: 26840026
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram.
Malka F; Dairou J; Ragunathan N; Dupret JM; Rodrigues-Lima F
FEBS J; 2009 Sep; 276(17):4900-8. PubMed ID: 19664055
[TBL] [Abstract][Full Text] [Related]
9. Human arylamine N-acetyltransferase 1: in vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines.
Liu L; Wagner CR; Hanna PE
Chem Res Toxicol; 2008 Oct; 21(10):2005-16. PubMed ID: 18759501
[TBL] [Abstract][Full Text] [Related]
10. Cadmium alters the biotransformation of carcinogenic aromatic amines by arylamine N-acetyltransferase xenobiotic-metabolizing enzymes: molecular, cellular, and in vivo studies.
Ragunathan N; Dairou J; Sanfins E; Busi F; Noll C; Janel N; Dupret JM; Rodrigues-Lima F
Environ Health Perspect; 2010 Dec; 118(12):1685-91. PubMed ID: 20810355
[TBL] [Abstract][Full Text] [Related]
11. Human arylamine N-acetyltransferase 1: a drug-metabolizing enzyme and a drug target?
Rodrigues-Lima F; Dairou J; Busi F; Dupret JM
Curr Drug Targets; 2010 Jun; 11(6):759-66. PubMed ID: 20041842
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibition of the human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 by S-nitrosothiols.
Dairou J; Atmane N; Dupret JM; Rodrigues-Lima F
Biochem Biophys Res Commun; 2003 Aug; 307(4):1059-65. PubMed ID: 12878219
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.
Leggett CS; Doll MA; Salazar-González RA; Habil MR; Trent JO; Hein DW
Arch Toxicol; 2022 Feb; 96(2):511-524. PubMed ID: 34783865
[TBL] [Abstract][Full Text] [Related]
14. Cyanamide-mediated Inhibition of N-acetyltransferase 1.
Dierolf D; Scheitza S; Bonifas J; Blömeke B
Toxicology; 2012 Dec; 302(1):1-10. PubMed ID: 22835378
[TBL] [Abstract][Full Text] [Related]
15. Characterization of N-acetyltransferase 1 activity in human keratinocytes and modulation by para-phenylenediamine.
Bonifas J; Scheitza S; Clemens J; Blömeke B
J Pharmacol Exp Ther; 2010 Jul; 334(1):318-26. PubMed ID: 20406859
[TBL] [Abstract][Full Text] [Related]
16. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
17. Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants.
Dairou J; Petit E; Ragunathan N; Baeza-Squiban A; Marano F; Dupret JM; Rodrigues-Lima F
Toxicol Appl Pharmacol; 2009 May; 236(3):366-71. PubMed ID: 19248797
[TBL] [Abstract][Full Text] [Related]
18. Differences between murine arylamine N-acetyltransferase type 1 and human arylamine N-acetyltransferase type 2 defined by substrate specificity and inhibitor binding.
Laurieri N; Kawamura A; Westwood IM; Varney A; Morris E; Russell AJ; Stanley LA; Sim E
BMC Pharmacol Toxicol; 2014 Nov; 15():68. PubMed ID: 25432241
[TBL] [Abstract][Full Text] [Related]
19. The actinobacterium Tsukamurella paurometabola has a functionally divergent arylamine N-acetyltransferase (NAT) homolog.
Garefalaki V; Kontomina E; Ioannidis C; Savvidou O; Vagena-Pantoula C; Papavergi MG; Olbasalis I; Patriarcheas D; Fylaktakidou KC; Felföldi T; Márialigeti K; Fakis G; Boukouvala S
World J Microbiol Biotechnol; 2019 Oct; 35(11):174. PubMed ID: 31673919
[TBL] [Abstract][Full Text] [Related]
20. Resistance of Rhizobium strains to phygon, spergon, and thiram.
Odeyemi O; Alexander M
Appl Environ Microbiol; 1977 Apr; 33(4):784-90. PubMed ID: 869529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
